Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach
NCT ID: NCT00002682
Last Updated: 2018-10-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
5 participants
INTERVENTIONAL
1995-08-10
2001-10-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: Phase II trial to study the effectiveness of antibiotic therapy with amoxicillin, clarithromycin, tetracycline, and metronidazole plus antacids in patients with MALT lymphoma of the stomach.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Multi-center Study for Individual Treatment of Helicobacter Pylori Infection
NCT02689583
High Dose Amoxicillin Versus Tetracycline as Second-line Treatment of Resistant Helicobacter Pylori Infection
NCT02175927
Intraluminal Metronidazole Powder Monotherapy for Helicobacter Pylori Infection
NCT03524833
PPI-amoxicillin for H. Pylori Treatment
NCT05014685
A Multi-center Study for Eradication of Helicobacter Pylori With Triple Therapy Using Clarithromycin
NCT02923856
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
OUTLINE: All patients are treated on Regimen A; those receiving tetracycline on Regimen A are switched to Regimen B for their second course; those receiving amoxicillin for their first course receive tetracycline for their second course. Regimen A: Antibiotic Therapy with Gastric Acid Inhibition. Amoxicillin (or Tetracycline in penicillin-allergic patients); Clarithromycin; with Bismuth Subsalicylate; Omeprazole. Regimen B: Antibiotic Therapy with Gastric Acid Inhibition. Tetracycline; Metronidazole, METRO, NSC-50364; with Bismuth Subsalicylate; Omeprazole.
PROJECTED ACCRUAL: 75 patients will be entered over 3 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Antibiotic Treatment
Amoxicillin
Bismuth Subsalicylate
Clarithromycin
Metronidazole Hydrochloride
Omeprazole
Tetracycline Hydrochloride
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Amoxicillin
Bismuth Subsalicylate
Clarithromycin
Metronidazole Hydrochloride
Omeprazole
Tetracycline Hydrochloride
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
PRIOR CONCURRENT THERAPY: No concurrent chemotherapy or radiotherapy
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
M.D. Anderson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gideon Steinbach, MD, PhD
Role: STUDY_CHAIR
M.D. Anderson Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
MD Anderson Cancer Center Orlando
Orlando, Florida, United States
University of Texas - MD Anderson Cancer Center
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
UT MD Anderson Cancer Center website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MDA-CPPDM-95084
Identifier Type: -
Identifier Source: secondary_id
NCI-T95-0003D
Identifier Type: -
Identifier Source: secondary_id
CDR0000064361
Identifier Type: OTHER
Identifier Source: secondary_id
CPPDM95-084
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.